Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of MYC-driven tumor cells
US-10188630-B2 · Jan 29, 2019 · US
Methods for identifying therapeutic targets and treating monitoring cancers
US10676746B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10676746-B2 |
| Application number | US-201415038342-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2014 |
| Priority date | Nov 22, 2013 |
| Publication date | Jun 9, 2020 |
| Grant date | Jun 9, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides methods for treating cancers having a mutation in one or more tumor suppressor genes, comprising providing to a subject in need thereof an inhibitor of a kinase, as well as related methods and compositions.
First claim
Opening claim text (preview).
We claim: 1. A method for treating a pancreatic cancer in a subject in need thereof, wherein the pancreatic cancer comprises a mutation in a Kras gene, the method comprising providing to the subject an inhibitor of NUAK2. 2. The method of claim 1 , wherein the inhibitor inhibits expression of NUAK2. 3. The method of claim 1 , wherein the inhibitor inhibits an activity of NUAK2. 4. The method of claim 1 , further comprising providing to the subject cisplatin. 5. The method of claim 1 , wherein the pancreatic cancer is a primary tumor. 6. The method of claim 1 , wherein the method comprises determining whether the cancer comprises the mutation in the Kras gene before providing the inhibitor to the subject. 7. The method of claim 1 , wherein the method comprises determining a level of expression or activity of NUAK2 or the gene encoding NUAK2 in cancer cells obtained from the subject, before providing the inhibitor of NUAK2 to the subject. 8. The method of claim 1 , wherein the inhibitor comprises a polynucleotide that binds a NUAK2 gene or mRNA. 9. A method for inhibiting the growth and/or proliferation of pancreatic cancer cells comprising a mutation in a Kras gene, comprising contacting the cells with an inhibitor of NUAK2. 10. The method of claim 9 , wherein the inhibitor comprises a polynucleotide that binds a NUAK2 gene or mRNA.
Assignees
Inventors
Classifications
Double-stranded nucleic acids or oligonucleotides · CPC title
- C12N15/1137Primary
against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title
1,3-Thiazoles · CPC title
Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title
for cancer (immunoassay for cancer G01N33/575) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10676746B2 cover?
- The present invention provides methods for treating cancers having a mutation in one or more tumor suppressor genes, comprising providing to a subject in need thereof an inhibitor of a kinase, as well as related methods and compositions.
- Who is the assignee on this patent?
- Hutchinson Fred Cancer Res
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1137. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).